Table 2.

Demographic and clinical characteristics at 5-year follow-up

Sex (males/females)	30/20 (60.0%/40.0%)
Age (years)	69.3 ± 9.4 (43–85)
Disease duration (years)	17.8 ± 6.1 (6–31)
MDS-UPDRS-I	16.2 ± 8.2 (1–36)
MDS-UPDRS-II	22.4 ± 11.4 (3–44)
MDS-UPDRS-IV	6.5 ± 5.9 (0–24)
Total LEDD (mg)	960.0 ± 484.9 (200–2150)
NMSS	74.4 ± 55.9 (9–246)
SCOPA-AUT	21.3 ± 10.4 (6–48)
MoCA	22.9 ± 5.4 (10–29)
Dementia (yes/no)	15/35 (30.0%/70.0%)
Falls (yes/no)	31/19 (62.0%/38.0%)
Dysphagia (yes/no)	13/37 (26.0%/74.0%)
Postural instability (yes/no)	28/22 (56.0%/44.0%)
Dysarthria (yes/no)	18/32 (36.0%/64.0%)
PDQ-8 single index	41.0 ± 29.4 (0.0–93.7)

Results are reported as mean ± standard deviation (range) or absolute values (percentage), as appropriate

LEDD, Levodopa Equivalent Daily Dose; MDS-UPDRS, Movement Disorders Society Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; NMSS, Non-Motor Symptom Scale; PDQ-8, Parkinson’s Disease Questionaire-8; SCOPA-AUT, Scale for Outcomes in Parkinson’s Disease-Autonomic